CD274 and neuropathy: Although some case reports of neuropathy following atezolizumab treatments were reported in the literature (40–42), these differences in neurological adverse events reporting with anti-PD-L1 agents, in particular atezolizumab, compared to other ICIs have not been previously documented in the literature.